title: Clinical response to transurethral microwave thermotherapy is thermal dose dependent.
abstract: Transurethral microwave thermotherapy of the prostate was used to treat men with symptomatic benign prostatic hypertrophy. Three treatment protocols delivering increasing thermal doses (Prostasoft T-A > Prostasoft II > Prostasoft I) were evaluated. The results show a dose-dependent response. Histological changes induced by microwave heating were dependent on the temperature achieved in the tissue. Thermocoagulation is obtained above 45 degrees C and thermoablation above 60 degrees C. Using Prostasoft II in a long-term follow-up study, the Madsen symptom score decreased by 66% and peak flow rates increased by 41% over a period of more than 18 months. Using Prostasoft T-A (thermoablation) in 28 patients, a cavity was obtained inside the prostate without major complication. The symptoms and obstruction caused by benign prostatic hypertrophy can be treated by transurethral thermotherapy in a single, anesthesia-free 1-hour session on an ambulatory basis.
authors.affiliation: Antiquaille Hospital, Lyon, France.
authors.forename: M
authors.initials: M
authors.lastname: Devonec
authors.forename: C
authors.initials: C
authors.lastname: Ogden
authors.forename: P
authors.initials: P
authors.lastname: Perrin
authors.forename: S
authors.initials: S
authors.lastname: St Clair Carter
mesh_terms: D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008872:Microwaves; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D012984:Software; D014521:Urethra
chemical_list: D017430:Prostate-Specific Antigen